Perm Medical Journal
ISSN 0136-1449 (Print)
ISSN 2687-1408 (Online)
Menu
Archives
Home
About the Journal
Editorial Team
Editorial Policies
Author Guidelines
About the Journal
Issues
Search
Current
Articles in press
Retracted articles
Archives
Contact
Subscriptions
All Journals
User
Username
Password
Remember me
Forgot password?
Register
Notifications
View
Subscribe
Search
Search
Search Scope
All
Authors
Title
Abstract
Index terms
Full Text
Browse
By Issue
By Author
By Title
By Sections
Other Journals
Categories
BMJ Open News
The Lancet News
[19.10.2025] [Comment] Perioperative camrelizumab plus rivoceranib versus surgery in...
[19.10.2025] [Comment] The arrival of antibody drug conjugates in nasopharyngeal cancer
[20.10.2025] [Articles] Zanzalintinib plus atezolizumab versus regorafenib in refractory...
[19.10.2025] [Articles] Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug...
[19.10.2025] [Articles] Ivonescimab plus chemotherapy versus tislelizumab plus...
PubMed News Global
[19.10.2025] Guidelines on clinical practice of molecular tests in breast cancer in China...
[19.10.2025] Impact of office and home blood pressure control on cardiovascular events in...
[19.10.2025] YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
[19.10.2025] Stress and Support Present in Medical Crowdfunding in Pediatric Cancer
[19.10.2025] The Future of the Future: Artificial Intelligence in Transforming Primary and...
Current Issue
×
User
Username
Password
Remember me
Forgot password?
Register
Notifications
View
Subscribe
Search
Search
Search Scope
All
Authors
Title
Abstract
Index terms
Full Text
Browse
By Issue
By Author
By Title
By Sections
Other Journals
Categories
BMJ Open News
The Lancet News
[19.10.2025] [Comment] Perioperative camrelizumab plus rivoceranib versus surgery in...
[19.10.2025] [Comment] The arrival of antibody drug conjugates in nasopharyngeal cancer
[20.10.2025] [Articles] Zanzalintinib plus atezolizumab versus regorafenib in refractory...
[19.10.2025] [Articles] Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug...
[19.10.2025] [Articles] Ivonescimab plus chemotherapy versus tislelizumab plus...
PubMed News Global
[19.10.2025] Guidelines on clinical practice of molecular tests in breast cancer in China...
[19.10.2025] Impact of office and home blood pressure control on cardiovascular events in...
[19.10.2025] YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
[19.10.2025] Stress and Support Present in Medical Crowdfunding in Pediatric Cancer
[19.10.2025] The Future of the Future: Artificial Intelligence in Transforming Primary and...
Current Issue
Home
>
Archives
>
Vol 42, No 2 (2025)
>
PDF
Vol 42, No 2 (2025) - PDF (Russian)
Download this PDF file
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:
серия
ЭЛ № ФС 77 - 75489
от 05.04.2019 г
.
TOP